Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial
2015; Karger Publishers; Volume: 235; Issue: 1 Linguagem: Inglês
10.1159/000442026
ISSN1423-0267
AutoresJoão Figueira, Rufino Silva, José Henriques, Paulo Caldeira Rosa, Inês Laíns, Pedro Melo, Sandrina Nunes, José Cunha‐Vaz,
Tópico(s)Retinal and Optic Conditions
ResumoTo compare the efficacy and safety of intravitreal ranibizumab (IVR) in monotherapy or associated with panretinal photocoagulation (PRP) versus conventional PRP, for high-risk proliferative diabetic retinopathy (PDR) without vitreoretinal traction.Multicenter randomized trial, with 3 treatment arms: PRP versus IVR alone and PRP + IVR combined treatment. Follow-up was performed at months 3, 6 and 12.Thirty-five subjects were randomized and 32 used for analysis. Complete regression of neovessels elsewhere occurred in 100% (PRP + IVR), 75% (IVR) and 69.2% (PRP) and for neovessels of the disk in 44.4% (PRP + IVR), 37.5% (IVR) and 30.8% (PRP). During the 1-year duration of treatment, there was no need for laser rescue treatment in IVR-treated eyes.This trial suggests that the use of IVR is safe and may have a beneficial effect in the treatment of eyes with high-risk PDR.Ranibizumab appears to have a place in the treatment of PDR.
Referência(s)